Evidence map›Paper›PMID 38483630›Full record

ArticleSurgery today2024

Outcomes and pathologic response of primary lung cancer treated with tyrosine kinase inhibitor/immune checkpoint inhibitor before salvage surgery.

Masaru Takenaka, Fumihiro Tanaka, Kenta Kajiyama, Takehiko Manabe, Katsuma Yoshimatsu, Masataka Mori, Masatoshi Kanayama, Akihiro Taira, Taiji Kuwata, Aya Nawata and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Surgery today, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Masaru TakenakaSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. m-takenaka@med.uoeh-u.ac.jp.ORCID http://orcid.org/0000-0002-4436-2850
Fumihiro TanakaSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Kenta KajiyamaSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Takehiko ManabeSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Katsuma YoshimatsuSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Masataka MoriSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Masatoshi KanayamaSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Akihiro TairaSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Taiji KuwataSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Aya NawataDepartment of Pathology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Koji KurodaSecond Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
University of Occupational and Environmental Health Japan · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAdvances in primary lung cancer drug therapy have extended patients' survival, including patients with stage IV disease. This study assessed the safety and effectiveness of salvage surgery following tyrosine kinase inhibitor (TKI) or immune checkpoint inhibitor (ICI) therapy in primary lung cancer.

methodsA retrospective chart review was conducted of 2050 primary lung cancer surgeries performed at our institution between 2012 and 2022. The study included patients who underwent salvage surgery for unresectable lesions that became resectable or localized residual lesions after treatment. We investigated patients' clinicopathological characteristics, therapeutic responses, and survival outcomes.

resultsWe identified eight cases of salvage surgery after TKI treatment and eight cases after ICI treatment. Five patients experienced early recurrence after surgery; however, the long-term outcome in the post-TKI group was favorable, with a median overall survival (OS) of 66 (range: 28-80) months. Postoperative recurrence was confined to local lymph node recurrence in one patient in the post-ICI group. Despite the relatively short observation period, the long-term prognosis remained promising, with a median OS of 18.7 (range: 9.7-55.8) months.

conclusionsSalvage surgery after TKI or ICI treatment can be safely performed, and the OS may be favorable.

Indexed as

Immune Checkpoint InhibitorsLung NeoplasmsProtein Kinase InhibitorsSalvage TherapyAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesSurvival RateTime FactorsTreatment OutcomeImmune Checkpoint InhibitorsProtein Kinase InhibitorsTyrosine Kinase InhibitorsImmune checkpoint inhibitorLung cancerPathologic responseSalvage surgeryTyrosine kinase inhibitor

Identifiers

PMID38483630
OpenAlexW4392808685

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.